Get the Stockscreener App
2.06
7.62%
-0.17
Pre-market:
2.06
Annovis Bio Inc stock is traded at $2.06, with a volume of 1.52M.
It is down -7.62% in the last 24 hours and up +18.39% over the past month.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
See More
Previous Close:
$2.23
Open:
$2.27
24h Volume:
1.52M
Relative Volume:
1.61
Market Cap:
$87.64M
Revenue:
-
Net Income/Loss:
$-40.92M
P/E Ratio:
-1.20
EPS:
-1.7167
Net Cash Flow:
$-26.53M
1W Performance:
+6.19%
1M Performance:
+18.39%
6M Performance:
-58.13%
1Y Performance:
+4.04%
1-Day Range:
$2.05
$2.33
1-Week Range:
$1.75
$2.385
52-Week Range:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.06 | 94.87M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio regains NYSE listing compliance By Investing.com - Investing.com Nigeria
Biotech Annovis keeps NYSE listing after falling below $50M thresholds - Stock Titan
Annovis launches proposed public stock and warrant offering - MSN
Annovis Bio Analyst Ratings and Price Targets | NYSE:ANVS - Benzinga
ANVS Technical Analysis | Trend, Signals & Chart Patterns | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Bio director Michael Hoffman buys $142,778 in shares By Investing.com - Investing.com South Africa
Annovis Bio director Michael Hoffman buys $142,778 in shares - Investing.com UK
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Director Michael Hoffman adds 76,344 Annovis Bio (ANVS) shares in open-market buys - Stock Titan
Annovis Bio prices $15 million public offering at $1.90 - Investing.com UK
Annovis Bio Announces Dilutive Equity Offering for Trials - TipRanks
Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity - TradingView
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Annovis Bio (NYSE: ANVS) raises $13.8M via 7.895M-share offering and warrants - Stock Titan
Annovis Bio Prices $15 Million Public Offering to Fund Neurodegenerative Disease Trials - MEXC
Annovis Bio slips after pricing $15M equity offering - MSN
Annovis announces pricing of $15.0 million public offering of common stock and accompanying warrants - marketscreener.com
Annovis Bio prices $15 million public offering at $1.90 By Investing.com - Investing.com South Africa
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - The Manila Times
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Biotech Annovis prices $15M offer to fund Alzheimer’s, Parkinson’s studies - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio Launches Proposed Stock, Warrant Offering; Shares Fall - Moomoo
Annovis Bio stock tumbles on public offering announcement By Investing.com - Investing.com Nigeria
Annovis Bio announces public offering of stock and warrants By Investing.com - Investing.com South Africa
Annovis Bio (ANVS) registers equity units with detachable warrants in shelf supplement - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Annovis Bio stock tumbles on public offering announcement - Investing.com
Annovis Bio announces public offering of stock and warrants - Investing.com
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants - The Manila Times
Biotech Annovis plans stock-and-warrant sale for Alzheimer’s Phase 3 study - Stock Titan
Annovis Bio, Inc. Common Stock (NY: ANVS - The Chronicle-Journal
Annovis Bio, Inc. 1Q 2026: Net income $(17.61M), EPS $(0.63) — 10-Q Summary - TradingView
Rising R&D and going-concern risk at Annovis Bio (ANVS) as cash falls - Stock Titan
Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Annovis Bio Releases Q1 2026 Financial Results - AlphaStreet
Annovis Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results - The Manila Times
Press Release: Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results - Moomoo
ANVS Stock Price, Quote & Chart | ANNOVIS BIO (NYSE:ANVS) - ChartMill
TradingKey - TradingKey
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
ANVS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):